Outlook Therapeutics reports Q2 FY2024 net loss of $114.3M; positive CHMP opinion for ONS-5010 in EU

Outlook Therapeutics, Inc.

2024-Q2 EPS reported -$9.20

Net loss of $114.3M ($8.01/sh); adjusted net loss of $22.1M ($1.55/sh) vs $6.7M loss year ago.
CHMP issued positive opinion for ONS-5010/LYTENAVA in EU; EC decision expected within ~67 days.
NORSE EIGHT trial >30% enrolled; topline readout planned in Q4 CY2024; BLA resubmission by end of CY2024.
UK MAA submitted under International Recognition Procedure.
Company believes sufficient capital to fund potential FDA approval and commercial launch assuming warrant exercise.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Outlook Therapeutics, Inc. reported financial results for second quarter of fiscal year 2024.

Period: second quarter of fiscal year 2024
Result: reported results

Exact text from the filing

Outlook Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for its second fiscal quarter ended March 31, 2024

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Outlook Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-062054

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.